Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany

Peer Review reports

Original Submission
12 Apr 2024	Submitted	Original manuscript
16 Apr 2024	Reviewed	Reviewer Report - Lanfranco Pellesi
25 Apr 2024	Reviewed	Reviewer Report
8 May 2024	Author responded	Author comments - Armin Scheffler
Resubmission - Version 2
8 May 2024	Submitted	Manuscript version 2
Publishing
9 May 2024	Editorially accepted
16 May 2024	Article published	10.1186/s10194-024-01788-1

Back to article page